Evaluation Of Complement C3 Inhibition In Ameliorating ALS Disease Phenotypes Using A Human-On-A-Chip Neuromuscular Junction System (MDA 2022) - Apellis Medical Hub

Evaluation Of Complement C3 Inhibition In Ameliorating ALS Disease Phenotypes Using A Human-On-A-Chip Neuromuscular Junction System

Share Via Email

Back to Conference Resources

ALS Congress Presentations MDA Clinical and Scientific Conference 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.